


Attorney Docket No.: PB60729USw

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of formula (I);



wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;


R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R³ is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C₃₋₈ cycloalkyl group, an unsubstituted or substituted straight or branched C₁₋₁₀ alkyl, an unsubstituted or substituted C₅₋₇ cycloalkenyl or R⁵;

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, or SO₂Me;

R⁵ is



wherein p is 0, 1 or 2, and X is CH₂, O, S, SO or SO₂;

Attorney Docket No.: PB60729USw

R^6 is (C_{3-6}) cycloalkyl, 4- to 7- membered non aromatic heterocyclic group or unsubstituted C_{2-6} alkyl or substituted (C_{1-6}) alkyl;

R^7 is OH, C_{1-6} alkoxy, $NR^{8a}R^{8b}$, $NHCO R^9$, $NHSO_2R^9$, SO_qR^9 ;

R^{8a} is H or C_{1-6} alkyl;

R^{8b} is H or C_{1-6} alkyl;

R^9 is C_{1-6} alkyl;

q is 0, 1 or 2;


and pharmaceutically acceptable derivatives thereof,

wherein R^6 is not CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3.

2. (Original) A compound as claimed in claim 1 wherein X is CH_2 , O or S.

3. (Currently Amended) A compound as claimed in claim 1 or 2 wherein R^6 is (C_{3-6}) cycloalkyl, 4- to 7- membered non aromatic heterocyclic group or unsubstituted C_{2-6} alkyl.

4. (Original) A compound as claimed in claim 1 wherein compounds of formula (I) are compounds of formula (Ia):



wherein:

R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group;

R^6 is unsubstituted or substituted C_{2-6} alkyl;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

d is 0, 1, 2 or 3;

and pharmaceutically acceptable derivatives thereof.

Attorney Docket No.: PB60729USw

5. (Currently Amended) A compound as claimed in ~~any one of~~ claims 1, ~~2 or 4~~ wherein R⁶ is either ethyl, substituted ethyl, isopropyl or tert-butyl.
6. (Canceled).
7. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claims 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.
8. (Original) A pharmaceutical composition as claimed in claim 7 further comprising a second therapeutic agent.
9. (Currently Amended) A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) ~~or (Ia)~~ as claimed in claims 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof.
10. (Currently Amended) A method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) ~~or formula (Ia)~~ as claimed in claims 1 ~~to 6~~ or a pharmaceutically acceptable derivative thereof.
11. (New) A pharmaceutical composition comprising a compound as claimed in claim 4 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.
12. (New) A pharmaceutical composition as claimed in claim 11 further comprising a second therapeutic agent.

Attorney Docket No.: PB60729USw

13. (New) A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (Ia) as claimed in claim 4 or a pharmaceutically acceptable derivative thereof.

14. (New) A method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (Ia) as claimed in claim 4 or a pharmaceutically acceptable derivative thereof.

15. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 or a pharmaceutical derivative thereof and at least one Cox-2 inhibitor.

16. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 or a pharmaceutical derivative thereof and at least one PDE4 inhibitor.

17. (New) A pharmaceutical composition comprising a compound as claimed in claim 4 or a pharmaceutical derivative thereof and at least one Cox-2 inhibitor.

18. (New) A pharmaceutical composition comprising a compound as claimed in claim 4 or a pharmaceutical derivative thereof and at least one PDE4 inhibitor.